Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

NewAmsterdam Pharma (NAMS) Consolidated Net Income (2023 - 2025)

Historic Consolidated Net Income for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$72.0 million.

  • NewAmsterdam Pharma's Consolidated Net Income fell 33254.04% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 1115.4%. This contributed to the annual value of -$241.6 million for FY2024, which is 3654.46% down from last year.
  • NewAmsterdam Pharma's Consolidated Net Income amounted to -$72.0 million in Q3 2025, which was down 33254.04% from -$17.4 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Consolidated Net Income's 5-year high stood at -$16.6 million during Q3 2024, with a 5-year trough of -$93.8 million in Q1 2024.
  • Its 3-year average for Consolidated Net Income is -$50.9 million, with a median of -$44.6 million in 2023.
  • As far as peak fluctuations go, NewAmsterdam Pharma's Consolidated Net Income skyrocketed by 6468.08% in 2024, and later plummeted by 33254.04% in 2025.
  • NewAmsterdam Pharma's Consolidated Net Income (Quarter) stood at -$49.5 million in 2023, then plummeted by 86.34% to -$92.2 million in 2024, then increased by 21.88% to -$72.0 million in 2025.
  • Its Consolidated Net Income was -$72.0 million in Q3 2025, compared to -$17.4 million in Q2 2025 and -$39.5 million in Q1 2025.